Novo Nordisk To Construct One Of World’s Largest Insulin Plants In Tianjin, China Biopharma Center

BEIJING - The Danish-headquartered biopharmaceutical outfit Novo Nordisk is building a massive, $400 million insulin plant in the Chinese east coast city of Tianjin to serve diabetes patients across China and Asia, according to company executives and government officials